Thomas LINGELBACH

About Thomas LINGELBACH

Thomas Lingelbach is the Chief Executive Officer of Valneva SE and a member of the company’s Board of Directors. In that capacity, he is one of the most prominent leaders of this listed European vaccine company, and a central figure in its long-term strategic direction. His career is closely tied to the vaccine industry, with more than 30 years of experience in senior executive and management roles. Before joining Valneva, Lingelbach held senior positions at Intercell, Novartis and Chiron. Valneva identifies him as the former CEO of Intercell and notes that he was the founding President and CEO of Valneva. This background gave him deep operational exposure to vaccine development, licensing and commercialization, as well as to the building of international healthcare organizations. His career therefore combines scientific understanding with executive leadership in a highly regulated sector. Valneva states that he has contributed, in different capacities, to the successful development and licensure of more than ten vaccines. That experience is highly relevant to his profile: it suggests strong familiarity with clinical development, regulatory pathways, manufacturing scale-up and cross-functional coordination across research, quality, commercial and corporate teams. He also brings a technical academic background, holding an engineering degree specialized in bioprocess engineering and further business administration training, which reinforces his ability to bridge science and corporate strategy. At Valneva, Lingelbach has played a key role in governance and strategic continuity. The company highlighted his position as CEO during its transition from a two-tier governance model to a board-led structure, underlining the importance of leadership efficiency and clearer corporate oversight as the business evolved. His mandate has been associated with the strengthening of Valneva’s executive organization, the execution of its vaccine pipeline and the company’s efforts to balance innovation with operational discipline. For stakeholders, Thomas Lingelbach stands out as a seasoned vaccine executive with a rare combination of scientific credibility, regulatory experience and corporate leadership. His profile is particularly relevant in a sector where successful execution depends on long development cycles, strong compliance standards and the ability to convert scientific assets into commercial value.